Cardiotoxicity of Vasodilators and Positive Inotropic/Vasodilating Drugs in Dogs: An Overview

References

• Traina V. M. The role of toxicology in drug research and development. Med. Res. Rev. 1983; 3: 43
   PubMed Web of Science ®Google Scholar
• Caldwell J. The current status of attempts to predict differences in drug metabolism. Drug Metab. Rev. 1981; 12: 221
   PubMed Web of Science ®Google Scholar
• Fletcher A. P. Drug safety tests and subsequent clinical experience. J. R. Soc. Med. 1978; 71: 693
   PubMed Web of Science ®Google Scholar
• Ruelius H. W. Extrapolation from animals to man: predictions, pitfalls and perspectives. Xenobiotica 1987; 17: 255
   PubMed Web of Science ®Google Scholar
• Rozman K. Disposition of xenobiotics: species differences. Toxicol. Pathol. 1988; 16: 123
   PubMed Web of Science ®Google Scholar
• Voisin E. M., Ruthsatz M., Collins J. ML, Hoyle P. C. Extrapolation of animal toxicity to humans: interspecies comparisons in drug development. Regul. Toxicol. Pharmacol. 1990; 12: 107
   PubMed Web of Science ®Google Scholar
• Clark B., Smith D. A. Metabolism and excretion of a chromone carboxylic acid (FPL 52757) in various animal species. Xenobiotica 1982; 12: 147
   PubMed Web of Science ®Google Scholar
• Smith D. A., Neale M. G. Metabolism and clearance of proxicromil. Studies in rat, hamster, rabbit, dog, squirrel monkey, cynomolgus monkey, baboon and man. Eur. J. Drug Metab. Pharamacokin. 1983; 8: 225
   PubMed Web of Science ®Google Scholar
• Gee S. J., Green C. E., Tyson C. A. Comparative metabolism of tolbutamide by isolated he-patocytes from rat, rabbit, dog and squirrel monkey. Drug Metab. Disp. 1984; 12: 174
   PubMed Web of Science ®Google Scholar
• Sullivan H. R., Hanasono G. K., Miller W. M., Wood P. G. Species specificity in the metabolism of nabilone. Relationship between toxicity and metabolic routes. Xenobiotica 1987; 17: 459
   PubMed Web of Science ®Google Scholar
• Johnson A. N. Comparative aspects of contraceptive steroids – effects observed in Beagle dogs. Toxicol. Pathol. 1989; 17: 389
   PubMed Web of Science ®Google Scholar
• Elliott G. A., Purmalis A., VanderMeer D. A., Denlinger R. H. The propionic acids. Gastrointestinal toxicity in various species. Toxicol. Pathol. 1988; 16: 245
   PubMed Web of Science ®Google Scholar
• Ennis M., Lorenz W., Kapp B., Luben L., Schmal A. Comparison of the histamine-releasing activity of cremophor El and some of its derivatives in two experimental models: the in vivo anaesthetized dog and in vitro rat peritoneal mast cells. Agents Actions 1985; 16: 265
   PubMedGoogle Scholar
• Molello J. A., Gerbig C. G., Robinson V. B. Toxicity of probucol in mice, rats, dogs and monkeys: demonstration of a species-specific phenomenon. Toxicol. Appl. Pharmacol. 1973; 24: 580
   PubMed Web of Science ®Google Scholar
• Williams P. D. The role of pharmacological profiling in safety assessment. Regul. Toxicol. Pharmacol. 1990; 12: 238
   PubMed Web of Science ®Google Scholar
• Detweiler D. K. Spontaneous and induced arterial disease in the dog: pathology and pathogenesis. Toxicol. Pathol. 1989; 17: 94
   PubMed Web of Science ®Google Scholar
• Schneider P. Hemodynamically induced heart lesions in the dog after administration of cardioactive substances. Exp. Pathol 1991; 40: 155
   Google Scholar
• Colucci W. S. Positive inotropic/vasodilator agents. Cardiol. Clinics 1989; 7: 131
   PubMedGoogle Scholar
• Mason D. T., Awan N. A., DeMaria A. N., Lee G., Amsterdam E. A. Vasodilator therapy of congestive heart failure. Drug Ther. 1978; 8: 30
   Google Scholar
• Colucci W. S., Wright R. F., Braunwald E. New positive inotropic agents in the treatment of congestive heart failure: mechanisms of action and recent clinical developments. N. Engl. J. Med. 1986; 314: 290
   PubMed Web of Science ®Google Scholar
• Colucci W. S., Wright R. F., Braunwald E. New positive inotropic agents in the treatment of congestive heart failure: mechanisms of action and recent clinical developments. N. Engl. J. Med. 1986; 314: 349
   PubMed Web of Science ®Google Scholar
• Smith T. W., Antman E. M., Friedman P. L., Blatt C. M., Marsh J. D. Digitalis glycosides: mechanisms and manifestations of toxicity. Prog. Cardiovasc. Dis. 1984; 26: 413
   PubMed Web of Science ®Google Scholar
• Dickstein K., Smith T. W. Current therapy of congestive heart failure. J. Cardiovasc. Pharmacol. 1989; 14(Suppl. 5)S48
   Google Scholar
• Parmley W. W. An overview of integration of therapy for congestive heart failure. J. Cardiovasc. Pharmacol. 1989; 14(Suppl. 5)S73
   PubMedGoogle Scholar
• Dei Cas L., Metra M., Visioli O. Clinical pharmacology of inodilators. J. Cardiovasc. Pharmacol. 1989; 14(Suppl. 8)S60
   Google Scholar
• Murray K. J. Cyclic AMP and mechanisms of vasodilation. Pharmacol. Ther. 1990; 47: 329
   PubMed Web of Science ®Google Scholar
• Siegl P. K.S. Overview of cardiac inotropic mechanisms. J. Cardiovasc. Pharmacol. 1986; 8(Suppl. 9)SI
   Google Scholar
• Honerjager P. Pharmacology of positive inotropic phosphodiesterase III inhibitors. Eur. Heart J. 1989; 10(Suppl. C)25
   PubMedGoogle Scholar
• Erdmann E. The value of positive inotropy in acute and chronic heart failure. J. Cardiovasc. Pharmacol. 1989; 14(Suppl. 3)S36
   Google Scholar
• Cook N. S. The pharmacology of potassium channels and their therapeutic potential. TIPS 1988; 9: 21
   PubMed Web of Science ®Google Scholar
• Edwards G., Weston A. H. Structure-activity relationship of potassium channel openers. TIPS 1990; 11: 417
   PubMed Web of Science ®Google Scholar
• Richter C., Pratz J., Mulder P., Mondot S., Giudicelli J. F., Cavero I. Cardiovascular and biological effects of K+ channel openers, a class of drugs with vasorelaxant and cardioprotective properties. Life Sci. 1990; 47: 1693
   PubMed Web of Science ®Google Scholar
• Edwards G., Weston A. H. Potassium channel openers and vascular smooth muscle relaxation. Pharamacol. Ther. 1990; 48: 237
   PubMed Web of Science ®Google Scholar
• Robertson D. W., Steinberg M. I. Potassium channel modulators: scientific applications and therapeutic promise. J. Med. Chem. 1990; 33: 1529
   PubMed Web of Science ®Google Scholar
• Goldberg M. R. Clinical pharmacology of pina-cidil, a prototype for drugs that affect potassium channels. J. Cardiovasc. Pharmacol. 1988; 12(Suppl. 2)S41
   Google Scholar
• Kinnunen P., Taskinen T., Leppaluoto J. Ruskoaho, Release of atrial natriuretic peptide from rat myocardium in vitro: effect of minoxidil-induced hypertrophy. Br. J. Pharmacol 1990; 99: 701
   PubMed Web of Science ®Google Scholar
• Baldoli E., Sardi A., Dezulian V., Capellini M., Bianchi G. On the pharmacology of 3-hydrazino-6-[N, N-bis(2-hydroxyethyl)amino]-pyri-dazine-dihydrochloride (L 6150). Arzneim. Forsch. 1973; 23: 1591
   PubMed Web of Science ®Google Scholar
• Greenberg S., Touhey B. Positive inotropy contributes to the hemodynamic mechanism of action of flosequinan (BTS 49465) in the intact dog. J. Cardiovasc. Pharmacol. 1990; 15: 900
   PubMed Web of Science ®Google Scholar
• Morgan H. E., personal communication
   Google Scholar
• Salzmann R., Bormann G., Herzig J. W., Markstein R., Scholtysik G. Pharmacological actions of APP 201–533, a novel cardiotonic agent. J. Cardiovasc. Pharmacol. 1985; 7: 588
   PubMed Web of Science ®Google Scholar
• Hoick M., Thorens S., Muggli R., Eigenmann R. Studies on the mechanism of positive inotropic activity of Ro 13–6438, a structurally novel cardiotonic agent with vasodilating properties. J. Cardiovasc. Pharmacol. 1984; 6: 520
   PubMed Web of Science ®Google Scholar
• Paciorek P. M., Cowlrick I. S., Perkins R. S. Ro 31 -6930, a novel potassium channel opener with smooth muscle relaxant and anti-hypertensive properties. Br. J. Pharmacol. 1989; 98: 722
   Google Scholar
• Mertens A., Muller-Beckmann B., Kampe W., Hoick J. P., von der Saal W. Non-steroidal cardiotonics. I. 2-Pyridyl-6,7-dihydro-3H,5H-pyr-rolol [2,3-f] benzimidazol-6-ones, a novel class of cardiotonic agents. J. Med. Chem. 1987; 30: 1279
   PubMed Web of Science ®Google Scholar
• Salzmann R., Scholtysik G., Markstein R., Bormann G. Pharmacological actions of DPN 205–734, a novel cardiotonic agent. J. Cardiovasc. Pharmacol. 1988; 12: 451
   PubMed Web of Science ®Google Scholar
• Coates W. J., Eden R. J., Emmett J. C., Gristwood R. W. SK&F 94120, a novel agent with positive inotropic and vasodilator activity. Br. J. Pharmacol. 1985; 84: 22P
   Google Scholar
• Gristwood R. W., Eden R. J., Owen D. A.A., Taylor E. M. Pharmacological studies with SK&F 94120, a novel positive inotropic agent with vasodilator activity. J. Pharm. Pharmacol. 1986; 38: 451
   Web of Science ®Google Scholar
• Fielden R., Owen D. A.A., Taylor E. M. Hypotensive and vasodilator actions of SK&F 24260, a new dihydropyridine derivative. Br. J. Pharmacol. 1974; 52: 323, 235
   PubMed Web of Science ®Google Scholar
• Reeves M. L., Gristwood R. W., Leigh B. K., England P. J. Sk&F 94836, a potent inotropic agent, is a selective inhibitor of type III phosphodiesterase activity from several tissues. Br. J. Pharmacol. 1987; 92: 773P
   Google Scholar
• Isaacs K. R., Joseph E. C., Betton G. R. Coronary vascular lesions in dogs treated with phosphodiesterase III inhibitors. Toxicol. Pathol. 1989; 17: 153
   PubMed Web of Science ®Google Scholar
• Roebel L. E., Dage R. C., Cheng H. C., Woodward J. K. In vitro and in vivo assessment of the cardiovascular effects of the cardiotonic drug MDL 1920 5,7. Cardiovasc. Pharmacol 1984; 6: 43
   PubMed Web of Science ®Google Scholar
• Kariya T., Wille L. J., Dage R. C. Studies on the mechanism of cardiotonic activity of MDL 19205: effects on several biochemical systems. J. Cardiovasc. Pharmacol. 1984; 6: 50
   PubMed Web of Science ®Google Scholar
• Dage R. C., Roebel L. E., Hsieh C. H., Weiner D. L., Woodward J. K. Cardiovascular properties of a new cardiotonic agent: MDL 17,043 (,3-dihydro-4-methyl-5-[4-(methy]thio)-benzoy]-2H-imidazol-2 -one). J. Cardiovasc. Pharmacol. 1982; 4: 500
   PubMed Web of Science ®Google Scholar
• Cheng H. C., Robinson P. J., Dage R. C., Jones W. D. MDL 27,032 relaxes vascular smooth muscle and inhibits protein kinase C. J. Cardiovasc. Pharmacol 1991; 17: 445
   PubMed Web of Science ®Google Scholar
• Pellegrini R., Abbondati G. Characteristics and clinical effects of ISF 2123, anew antihypertensive agent. Farmaco 1977; 32: 19
   Google Scholar
• Dorigotti L., Semeraro C. Renal function studies with propildazine alone and in combination with propranolol in dogs. Eur. J. Pharmacol 1980; 67: 275
   PubMed Web of Science ®Google Scholar
• Semeraro C., Dorigotti L., Banfl S., Carpi C. Pharmacological studies on cadralazine: a new antihypertensive vasodilator drug. J. Cardiovasc. Pharmacol 1981; 3: 455
   PubMed Web of Science ®Google Scholar
• Vos J., Dorhout Mees E. J. Clinical evaluation of a new antihypertensive vasodilating agent, PR-G 138 CI. Br. J. Clin. Pharmacol 1979; 8: 155
   PubMed Web of Science ®Google Scholar
• Baldoli E., Bianchi G., Corsico N., Di Francesco G. F. Pharmacological studies of N-(2,5-dimethyl- lH-pyrrol-1 -yl)-6(4-morpholinyl)-3-pyridazinamine hydrochloride (MDL-899), a new long-acting antihypertensive vasodilator. Arzneim. Forsch. 1985; 35: 818
   PubMed Web of Science ®Google Scholar
• Howden C. W., Elliott H. L., Lawrie C. B., Reid J. L. Pharmacodynamic studies in normal volunteers with MDL-899, a new arteriolar vasodilator. J. Cardiovasc. Pharmacol 1983; 5: 552
   PubMed Web of Science ®Google Scholar
• Salzmann R., Burki H., Chu D., Clark B., Marbach P., Markstein R., Reinert H., Siegl H., Waite R. Pharmakologische Wirkungen des Antihypertensivums 6-Benzoyl-3-hydrozino-5,6,7,8-tetrahydropyrido[4,3-c]pyridazin (BQ 22–708, Endralazine). Arzneim. Forsch. 1979; 29: 1843
   PubMedGoogle Scholar
• Kirch W., Axthelm T. Endralazine, a new peripheral vasodilator – a randomized crossover trial against dihydralazine. J. Cardiovasc. Pharmacol. 1982; 4: 562
   PubMed Web of Science ®Google Scholar
• Salzmann R., Gerber W., Pally C., Scholtysik G. Effects of the vasodilator endralazine given with the antihypertensive agent guanfacine on heart rate and blood pressure of spontaneously hypertensive rats and normotensive dogs. J. Pharm. Pharmacol 1983; 35: 293
   PubMed Web of Science ®Google Scholar
• Doxey J. C. Tolmesoxide, a drug that lowers blood pressure by a direct relaxant effect on vascular smooth muscle. Br. J. Pharmacol 1978; 63: 111
   PubMed Web of Science ®Google Scholar
• Honerjager P., Heiss A., Schafer-Korting M., Schonsteiner G., Reiter M. UD-CG 115, a cardiotonic pyridazinone which elevates cyclic AMP and prolongs the action potential in guinea-pig papillary muscle. Naunyn. Schmied. Arch. Pharmacol 1984; 325: 259
   PubMed Web of Science ®Google Scholar
• Verdouw P. D., Hartog J. M., Duncker D. J., Roth W., Saxena P. R. Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur. J. Pharmacol 1986; 26: 31
   Google Scholar
• Duncker D. J., Hartog J. M., Levinsky L., Verdouw P. D. Systemic haemodynamic activities of pimobendan (UD-CG 115 BS) and its O-desmethyl metabolite UD-CG 212 CL in the conscious pig. Br. J. Pharmacol 1987; 91: 609
   PubMedGoogle Scholar
• Weishaar R. E., Quade M., Schenden J. A., Boyd D. K., Evans D. B. Studies aimed at elucidating the mechanism of action of CI-914, a new cardiotonic agent. Eur. J. Pharmacol 1985; 119: 205
   PubMed Web of Science ®Google Scholar
• Bristol J. M., Sircar I., Moos W. H., Evans D. B., Weishaar R. E. Cardiotonic agents. I. 4,5-Dihydro-6-[4-(lH-imidazol-l-yl)phenyl]-3(2H)-pyridazinones : novel positive inotropic agents for the treatment of heart failure. J. Med. Chem. 1984; 27: 1099
   PubMed Web of Science ®Google Scholar
• Jafri S. M., Burlew B. S., Goldberg A. D., Olsen S., Froelich J. W., Goldstein S. Hemodynamic, pharmacokinetic and clinical response to CI-930 in congestive heart failure due to ischemic or dilated cardiomyopathy. Am. J. Cardiol. 1987; 59: 1126
   PubMed Web of Science ®Google Scholar
• Silver P. J., Hamel L. T., Bentley R. G., Dillon K., Connell M. J., O'Conner B., Ferrari R. A., Pagani E. D. Inhibitionof cardiovascular low-Km cAMP phosphodiesterase activity by medori-none. Drug Dev. Res. 1990; 21: 93
   Web of Science ®Google Scholar
• Alousi A., Canter J., Roth G., Montenaro M., Fort D., Hamel D. The inotropic and vaso-dilatory activity of medorinone in dogs. FASEB J. 1988; 2: A365
   Web of Science ®Google Scholar
• Alousi A. A., Canter J. M., Montenaro M. J., Fort D. J., Ferrari R. A. Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. J. Cardiovasc. Pharmacol 1983; 5: 792
   PubMed Web of Science ®Google Scholar
• Alousi A. A., Farah A. E., Lesher G. Y., Opalka C. J. Cardiotonic activity of amrinone – Win 40680. Circ. Res. 1979; 45: 666
   PubMed Web of Science ®Google Scholar
• Cohen M. L., Kurz K. D. Pinacidil-induced vascular relaxation: comparison to other vasodilators and to the classical mechanisms of vasodilation. J. Cardiovasc. Pharmacol. 1988; 12(Suppl. 2)S5
   Google Scholar
• Buckingham R. E., Clapham J. C., Hamilton T. C., Longman S. D., Norton J., Poyser R. H. BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models. J. Cardiovasc. Pharmacol. 1986; 8: 798
   PubMed Web of Science ®Google Scholar
• Berrett J. A., Woltmann R. F., Swillo R. S., Kasiewski C., Faith W. C., Campbell H. F., Perrone M. H. Pharmacology of RG W-938: a cardiotonic agent with vasodilator activity. J. Cardiovasc. Pharmacol. 1990; 16: 537
   PubMed Web of Science ®Google Scholar
• Mobley D., Mitchell J., Szatkowski M., Sit S. P. Effects of the novel PDE ID inhibitor R 80122 on the stunned myocardium in the anesthetized mi-cropig. FASEB J. 1990; 4: A735
   Google Scholar
• Schliep H. J., Becker K. H., Bergmann R., Haase A. F., Schelling P., Schulze E. Cardiovascular effects of EMD 52692, a novel potassium channel activator. Naunyn Schmied. Arch. Pharmacol. 1989; Suppl. 339: R62
   Google Scholar
• Falotico R., Moore J. B., Bandurco V., Bell S. C., Levine S. D., Tobia A. J. Cardiovascular properties of bemorinone: a new orally active quinazolinone cardiotonic agent. Drug Dev. Res. 1988; 12: 241
   Web of Science ®Google Scholar
• Combs D. W., Rampulla M. S., Bell S. C., Klaubert D. H., Tobia A. J., Falotico R., Haertlein B., Lakes-Weiss C., Moore J. B. 6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents. J. Med. Chem. 1990; 33: 380
   PubMed Web of Science ®Google Scholar
• Jafri S. M., Reddy B. R., Budzinski D., Goldberg A. D., Pilla A., Levine T. B. Acute neurohormonal and hemodynamic response to a new peak III phosphodiesterase inhibitor (ICI 153,110) in patients with chronic heart failure. J. Cardiovasc. Pharmacol. 1990; 16: 360
   PubMed Web of Science ®Google Scholar
• Collis M. G., Keddie J. R., Rouse W. The cardiovascular pharmacology of ICI 170777 ((6RS)-6-methyl-5- (pyrid-4- yl)-3H,6H-l,3,4- thiadiazin-2-one), a novel compound with positive inotropic and vasodilator effects. Br. J. Pharmacol. 1989; 97: 409
   PubMed Web of Science ®Google Scholar
• Quast U., Blarer S., Manley P. W., Cook N. S., Palley C., Fozard J. R. The cardiovascular effects of SDZ PCO 400 in vivo: comparison with cromakalim. Br. J. Pharmacol. Proc. Suppl. 1990; 99: 7P
   PubMedGoogle Scholar
• Mertens A., Friebe W. G., Muller-Bechmann B., Kampe W., Kling L., von der Staal W. Nonsteroidal cardiotonics. New 4,5-dihydro-6-(lH-indol-5-yl)pyridazin-3(2H)-ones and related compounds with positive inotropic activities. J. Med. Chem. 1990; 33: 2870
   PubMed Web of Science ®Google Scholar
• Strosberg A. M., Johnson L., Montgomery W., Lee C. H., Alvarez R., Bruno J. J., Jones G. H., Venuti M. C. RS-82856, a selective phosphodiesterase inhibitor with inotropic, afterload reduction and antithrombotic properties. Proc. West. Pharmacol. Soc 1987; 30: 5
   PubMedGoogle Scholar
• Alvarez R., Banerjee G. L., Bruno J. J., Jones G. L., Littschwager K., Strosberg A. M., Venuti M. C. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties. Mol. Pharmacol 1986; 29: 554
   PubMed Web of Science ®Google Scholar
• Bagli J., Bogri T., Palameta B., Rakhit S., Peseckis S., McQuillan J., Lee D. K.H. Chemistry and positive inotropic effects of pelrinone and related derivatives. A novel class of 2-methyl-pyrimidones as inotropic agents. J. Med. Chem. 1988; 31: 814
   PubMed Web of Science ®Google Scholar
• Morin M. E., Wojdan A., Oshiro G., Colatsky T., Quagliato D. Antihypertensive and hy-potentive effects of the potassium channel activator, Way-120,491 in spontaneously hypertensive, DOCA-salt, 2K-1C Goldblatt hypertensive and Wistar Kyoto normotensive rats. FASEB J. 1990; 4: A746
   Google Scholar
• Mondot S., Caillard C. G., James C., Aloup J. C., Cavero I. Antihypertensive and hemodynamic profile of 49356 RP, a novel vasorelaxant agent with potassium channel activating properties. Fundam. Clin. Pharmacol. 1989; 3: 158
   Google Scholar
• Lowenthal D. T., Affrime M. B. Pharmacology and pharmacokinetics of minoxidil. J. Cardiovasc. Pharmacol. 1980; 2(Suppl. 2)S93
   Google Scholar
• Herman E. H., Balazs T., Ferrans V. J., Young R. S.K. Divergent effects of propranolol and durosemide pretreatment on acute cardiomyopathy induced by minoxidil in Beagle dogs. Toxicology 1981; 20: 155
   PubMed Web of Science ®Google Scholar
• Balazs T., Herman E. H., Earl F. L., Wolff F. W. Cardiotoxicity studies with diazoxide, reser-pine, guanethidine, and combinations of diazoxide and propranolol in dogs. Toxicol. Appl. Pharmacol. 1975; 33: 498
   PubMed Web of Science ®Google Scholar
• Man int Veld A. J., Wenting G. J., Boomsma F., Verhoeven R. P., Schalekamp M. A. D. H. Sympathetic and parasympathetic components of reflex cardiostimulation during vasodilator treatment of hypertension. Br. J. Clin. Pharmacol 1980; 9: 547
   PubMed Web of Science ®Google Scholar
• Balazs T., Ferrans V. J., El-Hage A., Ehrreich S. J., Johnson G. L., Herman E. H., Atkinson J. C., West W. L. Study of the mechanism of hydralazine-induced myocardial necrosis in the rat. Toxicol. Appl. Pharmacol 1981; 59: 524
   PubMed Web of Science ®Google Scholar
• Koch-Weser J. Vasodilator drugs in the treatment of hypertension. Arch. Intern. Med. 1981; 133: 524
   Google Scholar
• Kauffman R. H., Utterbach B. G., Robertson D. W. Characterization and pharmacological relevance of high affinity binding sites for [3H]LY186126, a cardiotonic phosphodiesterase inhibitor, in canine cardiac membranes. Circ. Res. 1989; 65: 154
   PubMed Web of Science ®Google Scholar
• Kauffman R. F., Crowe V. G., Robertson D. W. The novel cardiotonic agent LY 195115 is a potent, competitive inhibitor of cyclic AMP phosphodiesterase located in the sarcoplasmic reticulum. Fed. Proc 1986; 45: 1049
   Google Scholar
• Hayes J. S., Pollock G. D., Wilson H., Bowling N., Robertson D. W. Pharmacology of LY 195115, a potent, orally active cardiotonic with a long duration of action. J. Cardiovasc. Pharmacol. 1987; 9: 425
   PubMed Web of Science ®Google Scholar
• Hayes J. S., Pollock G. D., Wilson H., Bowling N., Robertson D. W. Pharmacology of LY 175326: a potent cardiotonic agent with vasodilator activities. J. Pharmacol. Exp. Ther. 1985; 233: 318
   PubMed Web of Science ®Google Scholar
• Pouleur H., Rousseau M. F., van Mechelen H., Roncoroni L., Ries A., Charlier A. A. Cardiovascular effects of AR-L 115 BS in conscious dogs with and without chronic congestive heart failure. J. Cardiovasc. Pharmacol 1982; 4: 409
   PubMed Web of Science ®Google Scholar
• Berrett J. A., Woltmann R., Kasiewski C., Swillo R., Faith W. C., Pendleton R. G. Effect of WHR-2936, a new positive inotropic agent, in ganglionic-beta blocked dogs. Fed. Proc 1987; 46: 372
   Google Scholar
• Greenberg S. S., Paul J., Touhey B. Hemodynamic profile of the new cardiotonic agent CK-2289 compared to milrinone and enoximone in the anesthetized dog. Drug Dev. Res. 1991; 23: 109
   Web of Science ®Google Scholar
• Greenberg S., Touhey B. Hemodynamic and myocardial energetic effects of CK-3197, a selective positive inotropic agent. J. Cardiovasc. Pharmacol. 1991; 17: 145
   PubMedGoogle Scholar
• Jackson P. G., Jackson G., Kitson D., Jewitt D. E. The inotropic effects of UK 14,275, a phosphodiesterase inhibitor, in man. Br. J. Clin. Pharmacol. 1978; 5: 7
   PubMed Web of Science ®Google Scholar
• Shahid M., Roger I. W. Chronotropic and inotropic actions of amrinone, carbazeran and iso-butylmethyl xanthine: role of phosphodiesterase inhibition. Br. J. Pharmacol. 1989; 98: 291
   PubMed Web of Science ®Google Scholar
• Alabaster C. T., Bell A. S., Campbell S. F., Ellis P., Henderson C. G., Roberts D. A., Roberts K. S., Ruddock K. S., Samuels G. M.R., Stefaniak M. H. 2(lH)-Quinoli-nones with cardiac stimulant activity. I. Synthesis and biological activities of (six-membered heter-oaryl)-substituted derivatives. J. Med. Chem. 1988; 31: 2048
   PubMed Web of Science ®Google Scholar
• On N. T., Damani L. A., Ranee D. J. In vitro microsomal N-oxidation of 6-(pyridin-3-yl-quinolin-2-(lH)-one by different species. 1990, Abstr. presented at 12th Eur. Workshop on Drug Metabolism, Basel, Switzerland
   Google Scholar
• Paulus G., personal communication
   Google Scholar
• Shahid M., Cottney J. C., Nicholson C. D., Marshall R. J., Briun J. C., McLndewar I., Walker G. B., Dickson M., Wylie K., Fisher D. The biochemical effects of ORG 30029 in cardiac and vascular tissues. Br. J. Pharmacol. 1989; 96: 186P
   PubMedGoogle Scholar
• Galvan M., Schudt C. Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle. Nauyn. Schmied. Arch. Pharmacol 1990; 342: 221
   PubMed Web of Science ®Google Scholar
• Schudt C., Winder S., Muller B., Ukena D. Zardaverine as a selective inhibitor of phospho-diesterse isozymes. Biochem. Pharmacol 1991; 42: 153
   PubMed Web of Science ®Google Scholar
• Sircar I., Steffen R. P., Bobowski G., Burke S. E., Newton R. S., Weishaar R. E., Bristol J. A., Evans D. B. Cardiotonic agents. IX. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4 -(lH-imidazol-l-yl)phenyl] eth-enyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure. J. Med. Chem. 1989; 32: 342
   PubMed Web of Science ®Google Scholar
• Bergmann R., Eiermann V., Gericke R. 4-Heterocyclyloxy-2H-1 -benzopyran potassium channel activators. J. Med. Chem. 1990; 33: 2759
   PubMed Web of Science ®Google Scholar
• Farah A. E., Alousi A. A., Schwarz R. P. Positive inotropic agents. Annu. Rev. Pharmacol. Toxicol 1984; 24: 275
   PubMed Web of Science ®Google Scholar
• Mesfln G. M., Piper R. C., DuCharme D. W., Carlson R. G., Humphrey S. J., Zins G. R. Pathogenesis of cardiovascular alterations in dogs treated with minoxidil. Toxicol. Pathol 1989; 17: 164
   PubMed Web of Science ®Google Scholar
• Maseri A., Pesola A., L'Abbate A., Contini C., Magini G. Systemic and coronary hae-modynamic effects of the new hypotensive drug L 6150. J. Intern. Med. Res. 1976; 4: 402
   PubMed Web of Science ®Google Scholar
• Wynne R. D., Crampton E. L., Hind I. D. The pharmacokinetics and haemodynamics of BTS 49465 and its major metabolites in healthy volunteers. Eur. J. Clin. Pharmacol 1985; 28: 659
   PubMedGoogle Scholar
• Cowley A. J., Wynne R. D., Hampton J. R. Flosequinan as a third agent for the treatment of hypertension: a placebo controlled, double-blind study. Eur. J. Clin. Pharmacol 1987; 33: 203
   PubMed Web of Science ®Google Scholar
• Kessler P. D., Packer M., Medina N., Yushak M. Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49464), a new direct-acting vasodilator drug, in severe chronic congestive heart failure. J. Cardiovasc. Pharmacol 1988; 12: 6
   PubMed Web of Science ®Google Scholar
• Belz G. G., Stern H. C., Butzer R. Dose-response following single administration of a new cardiac performance enhancer, Ro 13–6438, in normal volunteers. J. Cardiovasc. Pharmacol 1985; 7: 86
   PubMed Web of Science ®Google Scholar
• Peters P., Saborowski F., May E., Schneider M. Zentrale haemodynamik unter der neuen positiv inotropen Substanz Adibendan. Arz-neim. Forsch. 1990; 40: 666
   PubMedGoogle Scholar
• Nemanich J. W., Shurman A. J., Rossen J. D., Kremser C., Davis F., Rajfer S. I. Effects of long-term therapy with oral piroximine on resting hemodynamics, peak aerobic capacity, and the anaerobic threshold in patients with heart failure. J. Cardiovasc. Pharmacol 1987; 10: 580
   PubMed Web of Science ®Google Scholar
• Uretsky B. F., Generalovich T., Verbalis J. G., Valdis A. M., Reddy P. S. MDL 17,043 therapy in severe congestive heart failure: characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical response. J. Am. Coll. Cardiol. 1985; 5: 1414
   PubMed Web of Science ®Google Scholar
• Arbogast R., Brandt C., Haegele K. D., Fincker J. L., Schechter P. J. Hemodynamic effects of MDL 17,043, a new cardiotonic agent, in patients with congestive heart failure: comparison with sodium nitroprusside. J. Cardiovasc. Pharmacol. 1983; 5: 998
   PubMed Web of Science ®Google Scholar
• Buoniconti R., Motolese M. Antihypertensive activity of a new vasodilator, cadralazine, administered alone or in combination with a beta-blocker. Int. J. Clin. Pharmacol. Ther. Toxicol. 1985; 23: 613
   PubMedGoogle Scholar
• Shanks R. G., Balnave K., Russell C. The effects of cyclosidimine, a peripheral vasodilator drug, on blood pressure and heart rate in healthy subjects. Br. J. Clin. Pharmacol. 1984; 18: 232
   PubMed Web of Science ®Google Scholar
• Blumenthal H. P., Ryan J. R., McMahon F. G. Initial clinical experience with a peripheral vasodilator, PR-G-138C1, inhypertensive patients. Eur. J. Clin. Pharmacol. 1975; 8: 409
   PubMed Web of Science ®Google Scholar
• Elliott H. L., Campbell L., Sumner D. J., Reid J. L. Clinical evaluation of the vasodilator MDL-899 in patients with essential hypertension. J. Cardiovasc. Pharmacol. 1985; 7: 948
   PubMed Web of Science ®Google Scholar
• Quyyumi A. A., Wagsteff D., Evans T. R. Acute hemodynamic effects of endralazine: a new vasodilator for chronic refractory congestive heart failure. Am. J. Cardiol. 1983; 51: 1353
   PubMed Web of Science ®Google Scholar
• Silas J. H., Phillips F. C., Freestone S., Tucker G. T., Ramsay L. E. A clinical and pharmacokinetic evaluation of tolmesoxide in hypertensive patients. Eur. J. Clin. Pharmacol. 1981; 19: 113
   PubMed Web of Science ®Google Scholar
• Lauwers P., Nievel J. G. Haemodynamic changes in heart failure induced by a new vasodilator tolmesoxide. Eur. J. Clin. Pharmacol. 1982; 21: 473
   PubMed Web of Science ®Google Scholar
• Hagemeijer F., Brand H. J., Roth W. Cardiovascular effects and plasma level profile of pi-mobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing. J. Cardiovasc. Pharmacol. 1989; 14: 302
   PubMed Web of Science ®Google Scholar
• Peters P., Saborowski F., Kothe A. Ein-fluss von Pimobendan auf die periphere Haemodynamik. Z. Kardiol. 1989; 78: 538
   PubMedGoogle Scholar
• Jafri S. M., Burlew B. S., Goldberg A. D., Rogers A., Goldstein S. Hemodynamic effects of a new type III phosphodiesterase inhibitor (CI-914) for congestive heart failure. Am. J. Cardiol. 1986; 57: 254
   PubMed Web of Science ®Google Scholar
• Borow K. M., Come P. C., Neuman A., Bairn D. S., Braunwald E., Grossman W. Physiologic assessment of the inotropic, vasodilator and afterload effects of milrinone in subjects without cardiac disease. Am. J. Cardiol. 1985; 55: 1204
   PubMed Web of Science ®Google Scholar
• Kubo S. H., Cody R. J., Chatterjee K., Simonton C., Rutman H., Leonard D. Acute dose range study of milrinone in congestive heart failure. Am. J. Cardiol. 1985; 55: 726
   PubMed Web of Science ®Google Scholar
• Benotti J. R., Grossman W., Braunwald E., Carabello B. A. Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease. Circulation 1980; 62: 28
   PubMed Web of Science ®Google Scholar
• Kardel T., Hilden T., Carlsen J., Trap-Jensen J. N″-cyano-N-4-pyridyl-N′-l,2,2-trime-thylpropylguanidine, a new vasodilating agent: acute effect on blood pressure and pharmacokinetics in hypertensive patients. J. Cardiovasc. Pharmacol. 1981; 3: 1002
   PubMed Web of Science ®Google Scholar
• Fox J. S., Whitehead E. M., Shanks R. G. Cardiovascular effects of cromakalim (BRL 34915) in healthy volunteers. Br. J. Clin. Pharmacol. 1991; 32: 45
   PubMed Web of Science ®Google Scholar
• Donelley R., Elliott H. L., Meredith P. A., Reid J. L. Clinical studies with the potassium channel activator cromakalim in normotensive and hypertensive subjects. J. Cardiovasc. Pharmacol. 1990; 16: 790
   PubMed Web of Science ®Google Scholar
• van Wayjen R. G. A. v.d., Ende A., Schuijt C. A double blind crossover tolerance study of AR-L 115 BS in healthy volunteers. Arzneim. Forsch. 1981; 31: 242
   PubMed Web of Science ®Google Scholar
• Follath F., Kersting F., Lewis G. R.J., Walden R. J., Woolhouse N. M., Dollery C. T. Cardiovascular effects of a new inotropic drug in dog and normal man. Clin. Pharmacol. Ther. 1976; 20: 24
   PubMed Web of Science ®Google Scholar
• Vatner S. F., Higgins C. B., Braunwald E. Sympathetic and parasympathetic components of reflex tachycardia induced by hypotension in conscious dogs with and without heart failure. Cardiovasc. Res. 1974; 8: 153
   PubMed Web of Science ®Google Scholar
• Sardi A., Caravaggi A. M., Baldoli E. Hemodynamic activity of L 6150. Naunyn. Schmied. Arch. Pharmacol. 1973; 279: 301
   PubMed Web of Science ®Google Scholar
• Falotico R., Haertlein B. J., Lakas-Weiss C. S., Salata J. J., Tobia A. J. Positive inotropic and hemodynamic properties of flosequinan, a new vasodilator, and a sulfone metabolite. J. Cardiovasc. Pharmacol. 1989; 14: 412
   PubMed Web of Science ®Google Scholar
• Sim M. F., Yates D. B., Parkinson R., Cooling M. J. Cardiovascular effects of the novel arteriovenous dilator agent, flosequinan in conscious dogs and cats. Br. J. Pharmacol. 1988; 94: 371
   PubMed Web of Science ®Google Scholar
• Eigenmann R., Gerold M., Hoick M. Cardiovascular profile of Ro 13–6428, a novel positive inotropic agent with vasodilating properties. J. Car-diovasc. Pharmacol. 1984; 6: 511
   PubMed Web of Science ®Google Scholar
• Paciorek P. M., Burden D. T., Burke Y. M., Cowlrick I. S., Perkins R. S., Taylor J. C., Waterfall J. F. Preclinical pharmacology of Ro 31–6930, a new potassium channel opener. J. Car-diovasc. Pharmacol 1990; 15: 188
   PubMed Web of Science ®Google Scholar
• Dorszewski A., Muller-Beckmann B., Kling L., Sponer G. Hemodynamic profile of an inhibitor of phosphodiesterase HJ, adibendan (BM 14,478): a comparison with nitroprusside and dobutamine in conscious dogs. Br. J. Pharmacol. 1990; 101: 686
   PubMed Web of Science ®Google Scholar
• Dage R. C., Roebel L. E., Hsieh C. P., Woodward J. K. Cardiovascular properties of a new cardiotonic agent, MDL 19.205. J. Cardiovasc. Pharmacol. 1984; 6: 35
   PubMed Web of Science ®Google Scholar
• Carpi C., Dorigotti L. Antihypertensive activity of a new 3-hydrazinopyridazine derivative: ISF 2123. Br. J. Pharmacol. 1974; 52: 459P
   Web of Science ®Google Scholar
• Higashio T., Tsuji Y., Nakoa K., Sakaguchi S., Tanaka M. Hemodynamic effects of cad-ralazine in hexamethonium treated and non-treated anesthetized dogs. Arzneim. Forsch. 1988; 38: 350
   PubMed Web of Science ®Google Scholar
• Dorigotti L., Ferni G., Lobroso M., Semeraro C. Hemodynamic profile of the antihypertensive vasodilator cadralazine in conscious dogs. Arzneim. Forsch 1984; 34: 984
   PubMed Web of Science ®Google Scholar
• Kitzen J. M., Lynch J. J., Driscoll E. M., Lucchesi B. R. Cardiac electrophysiologic and hemodynamic activity of pimobendan (UD-CG 115 BS), a new inotropic agent. J. Pharmacol. Exp. Ther. 1988; 244: 929
   PubMed Web of Science ®Google Scholar
• von Meel J. C.A. Cardiovascular effects of the positive inotropic agent pimobendan and sulmazole in vivo. Arzneim. Forsch 1985; 35: 284
   PubMed Web of Science ®Google Scholar
• Steffen R. P., Eldon C. M., Evans D. B. The effect of the cardiotonic imazodan (CI-914) on the myocardial and peripheral hemodynamics in the anesthetized dog. J. Cardiovasc. Pharmacol. 1986; 8: 520
   PubMed Web of Science ®Google Scholar
• Arrigoni-MarteUi E., Nielsen C. K., Ilsen U. B., Petersen H. J. N″-cyano-N-4-pyridyl-N′-1,2,2-trimethylpropylguanidine, monohydrate (P 1134): a new, potent vasodilator. Experientia 1980; 36: 445
   PubMedGoogle Scholar
• Kitzen J., Stupienski R., DeSiato M., Rovnyak L., Pirozzi C., Oshiro G., Colatsky T. Hemodynamic effects of WAY 120,491, pinacidil and cromakalim in anesthetized dogs. FASEB J. 1990; 4: A747
   Google Scholar
• DuCharme D. W., Freyburger W. A., Graham B. E., Carlson R. G. Pharmacologic properties of minoxidil: a new hypotensive agent. J. Pharmacol. Exp. Ther. 1973; 184: 662
   PubMed Web of Science ®Google Scholar
• Balazs T., Payne B. J. Myocardial papillary muscle necrosis induced by hypotensive agents in dogs. Toxicol. Appl. Pharmacol. 1971; 20: 442
   PubMed Web of Science ®Google Scholar
• Baum D., Halter J. B., Taborsky G. J., Porte D. Pentobarbital effects on plasma catecholamines: temperature, heart rate and blood pressure. Am. J. Physiol 1985; 248: E95
   PubMed Web of Science ®Google Scholar
• Boucher M., Dubray C., Li J. H., Paire M., Duchene-Marullaz P. Influences of pentobarbital and chloralose anesthesia on quinidine-in-duced effects on atrial refractoriness and heart rate in the dog. J. Cardiovasc. Pharmacol 1991; 17: 199
   PubMed Web of Science ®Google Scholar
• Rubin A. A., Zitowitz L., Hauser L. Acute circulatory effects of diazoxide and sodium nitrate. J. Pharmacol Exp. Ther. 1963; 140: 46
   PubMed Web of Science ®Google Scholar
• Spokas E. G., Wang H. H. Regional blood flow and cardiac responses to hydralazine. J. Pharmacol. Exp. Ther. 1980; 294: 212
   Google Scholar
• Levine T. B., Francis G. S., Goldsmith S. R., Simon A. B., Cohn J. N. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am. J. Cardiol 1982; 49: 1659
   PubMed Web of Science ®Google Scholar
• Grose R., Strain J., Greenberg M., Lejemtel T. H. Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure. J. Am. Coll. Cardiol 1986; 7: 1107
   PubMed Web of Science ®Google Scholar
• Montrad E. S., Bairn D. S., Smith H. S., Lanoue A., Braunwald E., Grossman W. Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure. Circulation 1985; 71: 972
   PubMed Web of Science ®Google Scholar
• Monrad E. S., Bairn D. S., Smith H. S., Lanoue A. S. Milrinone, dobutamine and nitroprusside: comparative effects of hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation 1986; 73(Suppl. Ill)168
   Google Scholar
• Carlson R. G., Feenstra E. S. Toxicologic studies with the hypotensive agent minoxidil. Toxicol. Appl. Pharmacol 1977; 39: 1
   PubMed Web of Science ®Google Scholar
• Herman E. H., Balazs T., Young R., Earl F. L., Krop S., Ferrans V. J. Acute cardiomopathy induced by the vasodilating agent minoxidil. Toxicol. Appl. Pharmacol 1979; 47: 493
   PubMed Web of Science ®Google Scholar
• Mesfin G. M., Shawaryn G. G., Higgins M. J. Cardiovascular alterations in dogs treated with hydralazine. Toxicol. Pathol 1987; 15: 409
   PubMed Web of Science ®Google Scholar
• Teske R. H., Bishop S. P., Righter H. P., Detweiler D. K. Subacute digoxine toxicosis in the Beagle dog. Toxicol. Appl. Pharmacol 1976; 35: 283
   PubMed Web of Science ®Google Scholar
• Harleman J. H., Joseph E. C., Eden R. J., Walker T. F., Major I. R., Lamb M. S. Cardiotoxicity of a new inotrope/vasodilator drug (SK&F 94120) in the dog. Arch. Toxicol 1986; 59: 51
   PubMed Web of Science ®Google Scholar
• DiFonzo C. J., Gebhart A. M., Gracon S. I., Fitzgerald J. E., Sturgess J. M., de la Iglesia F. A. Intravenous toxicology of a novel cardiotonic agent. Toxicologist 1984; 4: 6
   Google Scholar
• Gracon S. I., DiFonzo C. J., Fitzgerald J. E., Sturgess J. M., de la Iglesia F. A. Oral toxicity evaluation of a novel cardiotonic. Toxicologist 1984; 4: 7
   Google Scholar
• de la Iglesia F. A., personal communication
   Google Scholar
• de Wit R. H., Peter G. K., Fitzgerald J. E., de la Iglesia F. A. Preliminary toxicologic evaluation of a novel cardiotonic agent. Toxicologist 1985; 5: 94
   Google Scholar
• Rogers S., Barsoum N., DiFonzo C., Gracon S., Houston B., Martin R., Smith G., Sturgess J., de la Iglesia F. A. Intravenous toxicology of a new cardiotonic agent. Toxicologist 1985; 5: 111
   Google Scholar
• de la Iglesia F. A., personal communication
   Google Scholar
• Schneider P., personal communication
   Google Scholar
• Sandusky G. E., Means J. R., Todd G. C. Comparative cardiovascular toxicity in dogs given inotropic agents by continuous intravenous infusion. Toxicol. Pathol. 1990; 18: 268
   PubMed Web of Science ®Google Scholar
• Macallum G. E., Walker R. M., Barsoum N. J., Smith G. S., Greaves P. Preclinical toxicity of an adenosine agonst, CI-936. Toxicologist 1989; 9: 178
   Google Scholar
• Gans J. H., Korson R., Cater M. R., Ackerly C. C. Effects of short-term and long-term theobromine administration to male dogs. Toxicol. Appl. Pharmacol. 1980; 53: 481
   Google Scholar
• de la Iglesia F. A., personal communication
   Google Scholar
• Herman E., Balazs T., Young R., Krop S. Assessment of the acute cardiotoxic potential of sodium nitroprusside infusions in Beagle dogs. Toxicol. Appl. Pharmacol. 1978; 46: 55
   PubMed Web of Science ®Google Scholar
• Alousi A. A., Dobreck H. P. Amrionone, in. New Drugs Annual: Cardiovascular Drugs, A. Serabine. Raven Press, New York 1983; 259
   Google Scholar
• Alousi A. A., Fabian R. J., Baker J. F., Stroshane R. M. Milrinone, in. New Drugs Annual: Cardiovascular Drugs, A. Scrabine. Raven Press, New York 1985; 245
   Google Scholar
• Sandusky G. E., Means J. R. Acute and subchronic toxicology of LY-195115 in rats and dogs. Toxicol. Lett. 1987; 38: 177
   PubMed Web of Science ®Google Scholar
• Leslie G. B., Owen D. A.A., Pollitt F. D., Sutton T. J., Walker T. F. Short-term tox-icological studies with impromidine (SK&F 92676): a specific histamine H2-receptor agonist. J. Appl. Toxicol. 1982; 2: 265
   PubMed Web of Science ®Google Scholar
• Schneider P., Bauer M., Eckenfels A., Lehman H., Lutzen L., Ueberberg H. Tierexperi-mentele Untersuchung zur Vertraeglichkeit von AR-L 115 BS. Arzneim. Forsch. 1981; 31: 226
   PubMedGoogle Scholar
• Allen J. L., Post C. D., Detweiler D. K., Means J. R., Kotsonis F. N. Delayed cardiac damage in dogs following chronic treatment with oxagrelate (phthalazinol). Toxicologist 1986; 6: 202
   Google Scholar
• Means J. R., Franklin R. B., Sandusky G. E. Toxicological evaluation of the cardiotonic isomazole in the dog. Fundam. Appl. Toxicol. 1989; 13: 418
   PubMedGoogle Scholar
• Durant G. J., Ducan W. A.M., Ganellin C. R., Parsons M. E., Blackmore R. C., Rasmussen A. C. Impromidine (SK&F 92676) is a very potent and specific agonist for histamine H2 receptors. Nature 1978; 276: 403
   PubMed Web of Science ®Google Scholar
• Lokhandwala M. F. Pharmacological analysis of the tachycardia produced by histamine and specific HI- and. H2-receptor agonists in anesthetized dogs. Eur. J. Pharmacol 1978; 51: 351
   PubMed Web of Science ®Google Scholar
• Bode G., personal communication
   Google Scholar
• Schlappi B., personal communication
   Google Scholar
• Ettlin R. A., personal communication
   Google Scholar
• Kayne B., Offerman J. L., Reid J. L., Elliott H. L., Hills W. S. A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiotica 1984; 14: 935
   PubMed Web of Science ®Google Scholar
• Herman E. H., Ferrans V. J., Young R. S.K., Balazs T. A comparative study of minoxidil-induced myocardial lesions in beagle dogs and miniature swine. Toxicol. Pathol 1989; 17: 182
   PubMed Web of Science ®Google Scholar
• Wenger T. L., Masterton C. E., Abou-Donia M. B., Bache R. J., Strauss H. C. Myocardial procainamide concentration in canine atria and ventricles. J. Cardiovasc. Pharmacol 1979; 1: 155
   PubMed Web of Science ®Google Scholar
• Sobota J. T. Review of cardiovascular findings in humans treated with minoxidil. Toxicol. Pathol 1989; 17: 193
   PubMed Web of Science ®Google Scholar